Single dose of HPV vaccine: call for evidence from the JCVI
Call for evidence description
The Joint Committee on Vaccination and Immunisation (JCVI) is asking for evidence to support a review of possible changes to the human papillomavirus (HPV) immunisation programme.
JCVI is interested in relevant evidence to support consideration of the potential to move to a single-dose schedule of HPV vaccine for the routine programme and other alternative dose HPV schedules.
This call for evidence may be of particular interest to those who work in the field of HPV and immunisation, including:
- academics
- clinical researchers
- clinicians
- mathematical modellers
- health economists
- public health practitioners
- sexual health
- charities
- implementation commissioning and delivery
-
the pharmaceutical industry
Documents
Updates to this page
Published 18 March 2020Last updated 16 April 2020 + show all updates
-
The closing date for the call for evidence has been extended to 8 May 2020 to allow organisations more time to respond due to coronavirus (COVID-19).
-
First published.